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Hypertension 
By Ian Heslop 
learning objectives 
After reading this article you should: 
• Have an understanding of the classification and 
definitions of hypertension. 
• Understand the importance of combining 
absolute cardiovascular risk with blood pressure 
measurements in the diagnosis and assessment 
of hypertension. 
• Be aware of how appropriate first line 
antihypertensive agents are selected for individual 
patients and how the patient should be managed 
with those agents. 
• Have an understanding of the new National 
Heart Foundation of Australia guidelines for the 
management of hypertension and the recent 
reappraisal of the current role of beta blockers in 
the management of hypertension. 
Introduction 
Hypertension is krlOwn to be a major risk factor for coronary 
artery disease, heart fai I ure, renal disease and stroke and 
studies have demonstrated that approximately 20% of the 
world's population may be affected U I n Australia, like other 
western ised countries, the prevalence of hypertension is 
higher, with estimates suggesting that 29% of the Australian 
population is affected and 15% being untreated.4 In future 
years, the worldwide incidence of hypertension is expected 
to increase, due mainly to the effects of an increasingly 
ageing population and also the westernisation of lifestyles 
in developing countries.' It is assumed that this adopted 
'westernised lifestyle' will encourage associated increases 
in obesity, reduced physical exercise and increased dietary 
salt intake in those countries.5 For many years the diagnosis 
and management of hypertension has been an important issue 
for primary healthcare providers1,2 as it is a known modifiable 
risk factor for cardiovascular disease and the associated 
morbidity, mortality and economic burden of those diseases.! 
It is also recognised that hypertension is often poorly or 
under treated,5.6 and that compliance and persistence with 
antihypertensive medication is often poor.! Over the past two 
decades there have been regular reviews and revisions of the 
management guidelines for this condition with most recent 
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there are clear associations with hypertension and obesity, salt and alcohol 
intake.'·" 
discussions centring around a reappraisal of the role of beta 
blockers. New National Heart Foundation of Austra I ia (NHF) 
guidelinas for the management of hypertension have recently 
been released, as have National Institute for Health and 
Clinical Excellence (NICE) guidelines in the UK3j.lO This article 
is a brief review of the current management guideli nes for 
hypertension with a discussion of the reasoning behind the 
recent changes. 
Classifi cation 
Hypertension is generally classified into either essential 
(or primary) hypertension or secondary hypertension. Only 
5% of cases have easily identifiable causes such as renal 
disease, Cushing's disease, phaechromocytoma, pregnancy 
or medications such as corticosteroids, Destrogens, NSAIDs 
and alcohol and can therefore be classified as secondary 
hypertension. The vast majority (95%) of cases have no clear 
identifiable cause and are therefore classified as essential 
hypertension.1.11.12 
Epidemiology and pathophysiology 
Key epidemiological factors are age, gender and ethnic 
background. The prevalence of hypertension increases with 
age, and men are more likely to develop hypertension at an 
early age than women,! It is recognised that hypertension 
is more prevalent in black than white populations, with the 
prevalence of hypertension being reported as being 50% 
greater in African-American than Caucasian populations in 
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the USA.1 African-American and Afro-Caribbean populations 
also have lower renin activity and a poorer response to 
angiotensin-converting enzyme inhibitors (ACEls).1.13 An 
in-depth discussion of the causes and pathophysiology 
of hypertension is outside the scope of this article as they 
are both multifactorial and complex. But the development 
of hypertension is believed to be due to a combination of 
both genetic and environmental factors, and there are clear 
associations with hypertension and obesity, salt and alcohol 
intake. l .ll Arterial blood pressure is the product of cardiac 
output and peripheral vascular resistance and therefore blood 
pressure (and hypertension) is affected by factors which 
have an impact on these paramenters.1.13 These include 
factors such as stimulation of the sympathetic nervous 
system, renin-angiotensin-aldosterone system (RAAS) and 
parasympathetic nervous system as well as an interplay 
between the vasoactive substances produced by the vascular 
endothelium and a variety of other vasoactive mediators such 
as bradykinin, endothelin, endothelia I derived relaxi ng factor 
(EDRF) and atrial natri uretic peptide (ANP).113 
Clinical features 
Most cases of essential hypertenSion are asymptomatic, 
symptoms such as headache being more commonly 
experienced in secondary or malignant hypertension.1 The lack 
of symptoms is often a cause for non-compliance and poor 
Table 1: Definitions and classification of blood pressure 
levels (mmHgp 
Category Systolic Diastolic Follow up 
(mmHg} !mmHg) 
Normal < 120 <SO Recheck in 2 
years" 
High-normal 120-139 80-89 Recheck in 1 year* 
Grade 1 (mild) 140-159 90-99 Confirm within 2 
hypertension months** 
Grade 2 (moderate) 160-179 100-109 Reassess or refer 
hypertension within 1 month** 
Grade 3 (severe) ~180 ~110 Reassess or refer 
hypertension within 1-7 days as 
necessary*" 
Isolated systolic ~140 :;90 As for category 
hypertension corresponding to 
systolic BP 
Isolated systol ic ~160 :;;70 As for grade 3 
hypertension with hypertension 
widened pulse pressure 
N.B. If a patient's systolic and diastolic blood pressures fall into 
different categories, the higher category is applied 
.. or earlier depending on patient's absolute cardiovascular risk 
""or see when to intervene 
persistence with antihypertensiVe medication, as patients 
(and sometimes supporters) have poor insight into the long-
term health risks associated with untreated hypertension 
and discontinue therapy if side effects start to impact onto 
their lifestyle. If hypertension remains untreated, key organs 
within the body are chronically exposed to persistently 
high blood pressure resulting in end organ or target organ 
damage. Most organs are protected from this effect and 
maintain normal tissue blood flow, but key organs such as 
the kidney, heart, brain and eye may be affected resulting in 
hypertensive nephrOSis, left ventricular hypertrophy, increased 
risk of haemorrhagic strokes, dementia and hypertensive 
encephalopathyU 4 Hypertension has several effects on the 
eye and may cause hypertensive retinopathy, occlusion of the 
retinal vein and artery and ischaemic optic neuropathy.14 
Diagnosis and assessment 
A 'normal range' for blood pressure and a diagnostic level 
for hypertension is difficult to define as blood pressure is a 
continuous variable with a wide distribution in the general 
population.1 The International Society of Hypertension and 
World Health Organisation definition of hypertension, which 
is a sustained blood pressure of equal to or greater than 
140/90mmHg, is commonly quoted. I.12,13 But as patients 
often exhibit hypertenSion-related health problems at lower 
blood pressures it is important not to just consider blood 
pressure readings in isolation but also to consider absolute 
cardiovascular risk, both in the diagnosis and treatment of the 
condition.1 The measurement of blood pressure is fraught with 
inaccuracy due to a variety of patient-related or observer-
related factors. It is therefore important that diagnostic and 
therapeutic decisions are based on the presence of sustained 
elevated blood pfBssure measurements recorded on multiple 
occasions." Therapeutic decisions should not be made on 
isolated single resultsy·~·13 Blood pressure measurements 
should be made using an appropriate recommended and 
accurate technique and repeated several times if necessary.3 
A regularly serviced mercury sphygmomanometer should be 
used or the instrument should be regularly validated against 
a mercury sphygmomanometer. 3 The patient's blood pressure 
should be measured on both arms at the first assessment and 
then subsequent measurements should be made on the arm 
with the higher reading.3 The use of ambulatory or home blood 
pressure monitoring may help to identify patients with 'white 
coat hypertension' and prevent unnecessary treatment.3.I3,15 
White coat hypertension occurs in about 20% of patients 
with elevated blood pressure and although patients tend to 
have a lower cardiovascular risk than patients with sustained 
hypertension it may be a precursor of sustained hypertension 
and must be monitored.3.13 As the division between 
normotension and hypertension is arbitrary, it is important 
that the patient has a thorough clinical assessment with the 
aim of excluding and treating any possible secondary or drug-
induced causes of the hypertension and to assess the patient's 
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absolute cardiovascular riskuw Internationa I definitions of 
hypertension vary but the NHF Guidelines use the diagnostic 
levels and follow up recommendations listed in Table 1 with 
the recognition that individual cardiovascular risk assessment 
be used to determine the appropriate management for each 
patienP 
Absolute cardiovascular risk 
Absolute cardiovascular risk is the risk of a patient 
experiencing a cardiovascular event over a pre-defined 
period (usually five or 10 years)3 Elevated blood pressure 
is a major determinant of the risk of cardiovascular events 
such as myocardial infarction or stroke and other key risk 
factors include diabetes, cigarette smoking, male gender, 
and dyslipidaemia. Also, in Australia we must be aware of 
key ethnic risk groups such as Aboriginal and Torres Strait 
Islanders.3 All patients with confirmed hypertension should 
be assessed to identify all cardiovascular risk factors, detect 
end-organ damage and associated clinical conditions (Table 
2) and identify possible causes of secondary hypertension.3 
The new NHF guidelines recommend that high cardiovascular 
risk should be assumed for patients aged 75 years and over, 
patients with pre-existing cardiovascular disease and patients 
with associated cl inical conditions and end-organ disease 3 
All other patients should have their cardiovascular risk 
estimated using the modified New Zealand cardiovascular risk 
calculator.3 But it must be recognised that CV risk calculators 
may significantly underestimate the cardiovascular risk in 
Aboriginal, Torres Strait Islander, Maori or Pacific Islander 
peoples.3 Patients with high absolute cardiovascular risk 
(greater than 15% risk of a cardiovascular event within the 
next five years) need immediate antihypertensive therapy.3 
Management of hypertension 
When to initiate therapy 
All patients with confirmed hypertension should have a 
therapeutic plan aimed at reducing both blood pressure and 
absolute cardiovascular risk and the management strategies 
used will be related to the patient's absolute cardiovascular 
risk,u13 Figure 1, taken from the new NHF guidelines, 
summarises their current recommendations with regard 
to the stratification of therapy based on blood pressure 
measurements and absolute cardiovascular risk. The diagram 
shows that high risk patients should be treated immediately 
with lifestyle modification and drug treatment whereas 
moderate and mild risk patients are initially treated with 
lifestyle modification and undergo an appropriate period of 
monitoring before drug treatment is commenced,3 
Treatment goals 
Treatment goals for hypertension have gradually lowered in 
recent years as the relationship between blood pressure and 
outcome became better understood and it became evident 
that lower blood pressures are associated with better 
Figure 1: When to initiate blood pressure-lowering drug 
treatment3 
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outcomes.3,16 Table 3 summarises the treatment targets for 
adults from the current NHF guidelines,3 In most management 
guidelines it is recognised that targets such as these will be 
difficult to obtain in many patients, but it is accepted that any 
improvement in blood pressure and/or cardiovascu lar risk is 
beneficial.3.9 
Lifestyle modification 
Lifestyle modification is an important intervention and should 
form an integral part of the management of all patients, as 
it may abolish the need for medication in some patients and 
reduce the need in others.3,17.18 NHF recommendations centre 
around the 'SNAP' risk factors (Smoking cessation, Nutrition, 
Alcohol and Physical activityf.3 
Smoking cessation 
Although smoking cessation has little effect on blood pressure 
reduction, it is the most important lifestyle modification for 
reducing absolute cardiovascular risk.1.3,17 
- " 
r 
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Table 2: Associated clinical conditions and end-
organ disease3 
Associated clinical End-organ disease 
conditions (ACe) 
• Diabetes • left ventricular 
• Cerebrovascular disease hypertrophy 
o Ischaemic stroke • Microalbuminuria 
o Cerebral haemorrhage • Chronic kidney disease 
o Transient ischaemic • Vascular disease 
attack o Atherosclerotic 
• Coronary heart disease plaque evident 
o Myocardial infarction on ultrasound or 
o Angina radiology 
o Coronary o Hypertensive 
revascularisation retinopathy 
.. Chronic heart failure 
• Chronic kidney disease 
o Diabetic nephropathy 
o Glomerulonephritis 
o Hypertensive kidney 
disease 
• Aortic disease 
o Dissecting aneurysm 
o Fusiform aortic aneurysm 
• Peripheral arterial disease 
.. Hypercholesterolaemia 
• Fami Iy history of: 
o Premature cardiovascular 
disease 
o Familial 
hypercholesterolaemia 
Table 3: NHF treatment targets for adults3 
Patient group Blood pressure 
target (mmHg) 
Adults with proteinuria> 1 g/day (in <125/75 
people with/without diabetes) 
People with associated condition/s <130/80 
or end-organ damage: 
• Coronary heart disease 
.. Diabetes 
• Renal insufficiency 
.. Proteinuria 0.25-1.0g/day 
• Stroke/TIA 
People with none of the following: <140/90 
• Coronary heart disease or lower if tolerated 
• Diabetes 
• Renal insufficiency 
• Proteinuria (~D.25g/day 
• Stroke/TIA 
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Weight reduction 
Obesity is associated with the development of hypertension 
and weight loss has been proven to reduce blood pressure 
by an average of 2mmHg per kg of body weight los1.1.3·19 
Body mass index (BMI) is often used to define obesity but 
visceral adiposity appears to be more important in defining 
the relationship between obesity and blood pressure19 and 
patients' BMl and waist circumference should be assessed 
and monitored.3 The NHF recommends management goals of 
BMI of less than 25kg/m2 and a waist ci rcumference of 94cm 
for males and 8Dcm for females Dr less. 3 Patients should be 
advised that to reach and maintain a healthy weight they must 
make lifestyle changes that they can enjoy and maintain for a 
lifetime, which requires both increased physical activity and 
reduced energy intake.3 
Diet 
Studies have shown reductions in blood pressure of 5-7mmHg 
when sodium intake is reduced to 90-100mmol/day,u This 
may be further reduced if low salt intake is combined with 
a thiazide diuretic. \ Patients shou ld be encouraged to reduce 
their salt intake (less than 65mmol/day3) and avoid processed 
foods with a high salt content.o Potassium chloride may be 
sometimes used to substitute salt in the diet with no adverse 
effects' but care may be required in patients taking ACE 
inhibitors. Patients must also follow a diet low in saturated 
fat and high in plant-based foods l 
Alcohol 
The causal relationship has not been confirmed but there is a 
clear association between a Icohol intake and blood pressure 
in both sexes, with binge drinking being associated with the 
greatest risk.1.17 Abstinence from alcohol in hypertensive 
patients can reduce systolic blood pressure by 5~8mmHg.1 
Patients should be encouraged to reduce alcohol intake to 
safe drinking levelsu .17 (two standard drinks per day for men 
and one standard drink per day for women3) and to abstain 
where possible. 
PhYSical exercise 
Physical inactivity is a well recognised risk factor for 
cardiovascular disease and regular aerobic exercise can 
reduce blood pressure. All patients should be advised to 
become more active and have at least 30 minutes of moderate 
intensity physical activity on most if not all days of the 
week. Regular aerobic exercise can reduce blood pressure 
and patients should be advised to do at least 30 minutes of 
moderate intensity exercise on five or mom days per week. 3,17 
Pharmacological management 
Choice of first-line therapy 
The pharmacological management of hypertension has 
changed and evolved over the last 10-20 years. Until recently 
a traditional stepped care approach was recommended 
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involving a fairly dogmatic approach of using either beta 
blockers or low-dose thiazide diuretics as first line agents, 
followed by the addition of other antihypertensive agents if 
blood pressure control was not achieved. This was further 
developed into a more individualised stepped care approach, 
whereby an appropriate first I ine agent was chosen based on 
the patient's individual characteristics and factors such as:3,13 
.. The patient's cardiovascular risk profile 
.. The presence of target organ disease, clinical 
cardiovascular diseases, renal disease or diabetes 
• Contra indications with concomitant diseases or potential 
interactions with concomitant therapies 
.. Evidence for a reduction in cardiovascular events with the 
antihypertensive agent 
.. Social and lifestyle effects such as side effects and 
improved quality of life 
.. Economic factors such as the cost of therapy to both the 
patient and the hea Ith care system. 
Five common drug groups were recommended for the initial 
management of hypertension: the low-dose thiazide diuretics, 
the beta blockers, the angiotensin converting enzyme 
inhibitors (ACE Is), the angiotensin II receptor antagonists 
(A2RAs) and the ca Icium channel blockers (CCBs). As all 
were shown to reduce blood pressure to a similar extent 
but differed in their adverse effect profiles and COSV8.192U 
the selection of first line agent was based on their potential 
for favourable or unfavourable effects on any concomitant 
diseases. 
For many years beta blockers were widely used for first line 
treatment in hypertension and are sti II recommended as first 
line agents in some treatment guidelines. 21 .23 One explanation 
for their popularity was that studies confirmed the value of 
beta blockers after myocardial infarction (MIL in angina and 
in heart fai lure and clinicians made assumptions based on 
their effectiveness in the secondary prevention of coronary 
heart disease that they should also be effective for primary 
prevention in hypertension 2123 But the use of beta blockers 
for primary treatment of hypertension has been recently 
challenged 2! as comparisons with other antihypertensive 
agents showed them to be less effective in preventing major 
cardiovascular events such as stroke 2 .21.23 It was unclear 
Whether these conclusions applied to all beta blockers or on Iy 
to the drugs commonly used in hypertension trials (mainly 
atenolol), but researchers recommended that beta blockers 
should not remain the first choice agents for the treatment of 
primary hypertension. Z22•23 Beta blockers were also found to 
be less effective than ACEls and CCBs at reducing the risk of 
diabetes, especially when used in combination with thiazide 
diuretics.V.s 
These find ings were incorporated firstly into the 2006 update 
of the National Institute for Health and Clinical Excellence 
(NICE) and the British Hypertension Society recommendations 
for the pharmacological management of hypertension. The 
main recommendations were that beta blockers were no 
longer recommended for fi rst line management of any patient 
group and that CCBs and thiazides are recommended as 
first line agents in elderly and black people as they are the 
most clinically effective agents for lowering blood pressure 
in these patient groupS.2.7.S The updated NICE treatment 
recommendations are summarised in Figure 2. The current 
recommendation is that unless there are contra indications, 
Figure 2: Current NICE gu idel i nes for the 
treatment of hypertension7-9 
Key; 
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Further diuretic therapy. Or 
Alpha blocker. 0' Beta blocker. 
Consider seeking 'peciali.! advice. 
A = AGEl ,conside, A2RA if ACEI intolerantl 
C: Calcium channel blocker 
o = Thiazide diuretic 
Figure 3: NHF recommendations for initiating 
drug treatment for newly diagnosed 
uncompl icated hypertension3 
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ACEls shou ld be used for initial therapy i rl patients under the 
age of 55 years, whereas patients 55 years or older (or black 
patients) requiring drug treatment should be commenced on 
either a CCB or thiazide diuretic,)9 But the NICE guidelines do 
suggest that beta blockers may still be considered for younger 
patients, particularly women of childbearing potential, 
patients with evidence of increased sympathetic drive or 
patients intolerant of or who have contra indications to ACEls 
or A2RAs,) They also recommend that beta blockers should 
not be withdrawn if there is a compell ing reason for beta 
blocker use such as in angina or a previous MI.) 
In light of the recent findings regarding beta blockers, the NHF 
has now also reviewed its guideli nes for the management of 
hypertension; these are summarised in Figure 3, The new NHF 
guidelines discuss that ACEls (or A2RAs if the patient suffers 
from ACEI cough). dihydropyridine CCSs and low-dose thiazide 
diouretics are equally effective tor first line use for initial or 
maintenance therapy and the initial drug choice shou Id be 
based on:3 
Figure 4: NHF recommendations for stabilisation, 
maintenance and follow-up after initiation of 
antihypertensive therapy3 
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• The patient's age 
• The presence of associated clinical conditions and end-
organ damage 
• The presence of co-morbidities (and the favourable and 
unfavourable effects of the antihypertensive agent on 
these conditions) 
• Potential drug interactions 
• Implications for adherence 
• Cost 
Thiazide diuretics have been associated with increased risk 
of diabetes, therefore N HF recommends that the first-I ine use 
of thiazide diuretics should be limited to elderly patients (;;:65 
years of age) in whom the benefits of managing hypertension 
and reducing the risk of stroke outweigh the risk of diabetes,3 
Again for the reasons stated above, beta blockers are no 
longer recommended as first-line agents in uncomplicated 
hypertension although the guidelines state that it is 
reasonable to continue beta blocker therapy in patients with 
well-controlled hypertension already taking a beta blocker,' 
'Achieving target blood pressure3 
The aim ot therapy should be to achieve target blood 
pressure (Table 3) and combination therapy may be required 
to reach target levels.3 The lowest recommended dose of 
the first-line agent should be prescribed and the effect 
monitored. If the patient is unable to tolerate this agent it 
should be replaced with a drug from a different class, The 
patient should be monitored (Figure 4) and if target blood 
pressure is not reached, instead of increaSing the dose of 
the first agellt, a second agent (tram a different class) should 
be introduced at a low dose,S This approach is aimed at 
maximising the antihypertensive effect ot the agents whilst 
minimising side effects,3 Again the patient is monitored: if 
the blood pressure continues to be above target, the dose 
of one agent (but not the thiazide diuretic if being usedl is 
increased to the maximum recommended dose of the agent 
before increasing the dose of the second agent3 A stable 
response to a dose may take 3-4 weeks, Therefore dose 
increments should be made at six weekly intervals.s Once the 
regime is stable, combined preparations or the use of long-
acting agents that may be administered once daily may help 
adherence and compliance. s Combination therapy is required 
to reach target levels in 50-75% at patients and occasionally 
patients may requi re a combination of 3-4 agents, Table 4 
summarises commonly used combinations recommended 
in the NHF guidelines.s If the patient fails to respond to 
initial therapy with at least two agents the patient should 
be assessed for possible reasons, These may illclude non-
compliance, undiagnosed secondary hypertension, 'white coat' 
hypertension as well as other factors, but in some patients 
recommended target levels may not be achievable,3 
-. ~--~ .. , ~ ~ .. ~ ,. -
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Conclusions 
Hypertension is a major risk factor for cardiovascular 
disease and it is believed that the worldwide prevalence will 
increase in the future. Recent Australian and international 
gu idel ines for the management of hypertension recommend 
the assessment and treatment of patients with the aim of 
reducing both blood pressure and absolute cardiovascular risk 
to target levels. When appropriate, drug therapy should be 
utilised with lifestyle modification, and initial drug therapy 
will consist of ACE inhibitors, calcium channel blockers or 
low-dose thiazide diuretics with the choice of agent based on 
the presence of concomitant disorders and potential adverse 
effects.3,7·9.20 
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CPD questions on pages 586 
PliarriJ"acist 
Table 4: Recommended and non-recommended antihypertensive 
combinations from N HF Guidelines' 
Effective combinations 
Combination Notes 
ACEllor A2RAI + CCB Most effective combination 
- useful in the presence of 
diabetes or lipid abnormalities 
Thiazide diuretic + ACEI (or A2RAI Useful in the presence of heart 
failure or post stroke 
ACEI + A2RA Useful in people with both 
diabetes and chronic kidney 
disease 
ACEI + beta blocker Recommended post-MI or in 
people with heart failure 
Beta blocker + dihydropyridine CCB Useful in the presence of 
coronary heart disease 
Thiazide diuretic + CCB 
Beta blocker + alpha blocker Not recommended in people 
with glucose intolerance, 
metabol ic syndrome or 
diabetes 
Avoid the following combinations 
Combination Notes 
ACEI (or A2RAI + potassium sparing Risk of hyperkalaemia 
diuretic 
Beta blocker + verapamil or diltiazem Avoid combination with 
verapamil and caution with 
diltiazem due to risk of 
bradycardia and heart block 
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